Why take this course?
Continued Process Verification (CPV) requires organizations to maintain an ongoing state of control throughout commercial manufacturing, consistent with FDA Process Validation Guidance and ICH Q10 lifecycle principles. Although manufacturers routinely generate extensive process data, trend reports, investigations, and periodic reviews, many still face the practical challenge of distinguishing meaningful process signals from expected variation. As manufacturing environments become increasingly digital and data-rich, reviewing all information with equal intensity can reduce efficiency while obscuring emerging quality concerns.
This webinar examines how review-by-exception approaches strengthen CPV by directing attention toward signals that warrant investigation, escalation, or corrective action. The discussion addresses process trend interpretation, exception criteria, process drift, product quality risks, and evidence supporting intervention decisions. Practical examples demonstrate how exception-based review can improve oversight, reinforce confidence in process performance, and support consistent quality decisions while maintaining effective ongoing process verification throughout the commercial product lifecycle.
Key Areas Covered
Meredith Crabtree
Meredith Crabtree has more than 30 years of experience across pharmaceutical manufacturing, quality, packaging, labeling, regulatory assessments, inspections, and compliance training. Her background supporting regulated operations, third-party inspections, and quality system activities aligns directly with the practical process monitoring, oversight, and decision-making challenges addressed within Continued Process Verification programs.
Commonly Asked Questions About This Subject
How should organizations justify that a process remains in a state of control when process parameters gradually shift but specifications continue to be met?
Meeting specifications alone does not automatically demonstrate that a process remains well controlled. Inspection discussions often focus on gradual movement toward specification limits because those shifts may indicate changing process behavior long before product failures occur.
Documentation becomes difficult to defend when periodic reviews acknowledge a consistent directional trend yet conclude that no action is required solely because release criteria continue to be satisfied. Reviewers generally expect organizations to explain why the observed movement remains acceptable rather than simply noting that specifications were met.
Evidence carrying greater weight includes evaluation of historical process capability, relationship between critical process parameters and product quality, engineering assessment of contributing factors, and documented rationale supporting continued operation without intervention.
A well-supported conclusion demonstrates that the observed trend reflects understood process behavior instead of an early indication of process deterioration.
What makes exception thresholds difficult to defend during an inspection?
A direct answer is that thresholds become difficult to defend when they appear arbitrary or were established primarily to reduce review workload. Reviewers generally ask why a particular trend, variation, or statistical result deserves investigation while another does not.
Inspection friction develops when organizations cannot explain how thresholds were derived from process knowledge, validation evidence, product risk, historical performance, or scientific understanding. Statements such as "that has always been our limit" rarely provide sufficient justification.
Documentation supporting stronger exception criteria typically includes historical manufacturing data, process capability analysis, development knowledge, prior investigations, and periodic reassessment based on commercial experience.
Thresholds become substantially more defensible when they demonstrate a clear relationship to process understanding and product quality rather than functioning solely as administrative triggers for investigation.
When should recurring low-level process signals be treated as evidence of process drift rather than isolated events?
An operational failure point emerges when each signal is reviewed independently and found acceptable while the overall pattern gradually changes over time. Individual observations may not justify investigation, yet their combined behavior may indicate that the validated process is slowly moving away from established expectations.
Inspection observations frequently involve organizations that documented every event appropriately but never evaluated the cumulative trend. Small adjustments, repeated operator interventions, increasing process variability, or recurring minor deviations often reveal process changes that remain invisible during isolated reviews.
Evidence supporting earlier intervention includes documented trend analysis across multiple production campaigns, comparison with historical baselines, engineering assessment of recurring observations, and evaluation of whether process behavior remains consistent with validated performance.
Looking at the process generally provides a stronger basis for decision-making than reviewing each event independently.
How should management evaluate CPV program effectiveness beyond completion of periodic reviews?
A governance concern becomes visible when program success is measured primarily by the number of completed reports, meetings, or review cycles. Administrative completion demonstrates compliance with process requirements but provides limited evidence that the CPV program is strengthening manufacturing control.
Inspection discussions often shift toward the quality of decisions produced by the program. Reviewers examine whether emerging trends were recognized early, investigations were initiated appropriately, corrective actions addressed meaningful issues, and process improvements resulted from routine monitoring activities.
Documentation becomes considerably stronger when management periodically reviews the effectiveness of exception criteria, timeliness of investigations, recurrence of identified issues, and relationship between monitoring activities and actual product quality outcomes.
A mature CPV program demonstrates that monitoring information consistently supports informed operational decisions rather than serving primarily as evidence that scheduled reviews were completed.
Your TalkFDA Webinar Experience
1. Confirmation
3. Join the Live Training
4. Watch Again Anytime
Testimonials
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.


